Cargando…

PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma

A significant number of patients (pts) with metastatic melanoma do not respond to anti-programmed cell death 1 (PD1) therapies. Identifying predictive biomarkers therefore remains an urgent need. We retrospectively analyzed plasma DNA of pts with advanced melanoma treated with PD-1 antibodies, nivol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parakh, Sagun, Musafer, Ashan, Paessler, Sabrina, Witkowski, Tom, Suen, Connie S. N. Li Wai, Tutuka, Candani S. A., Carlino, Matteo S., Menzies, Alexander M., Scolyer, Richard A., Cebon, Jonathan, Dobrovic, Alexander, Long, Georgina V., Klein, Oliver, Behren, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220213/ https://www.ncbi.nlm.nih.gov/pubmed/34177913 http://dx.doi.org/10.3389/fimmu.2021.672521

Ejemplares similares

Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma
por: Da Gama Duarte, Jessica, et al.
Publicado: (2018)

Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses
por: Da Gama Duarte, Jessica, et al.
Publicado: (2021)

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation
por: Tutuka, Candani S. A., et al.
Publicado: (2017)

Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomes
por: Prithviraj, Prashanth, et al.
Publicado: (2020)

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations
por: Chang-Hao Tsao, Simon, et al.
Publicado: (2015)

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
por: Parakh, Sagun, et al.
Publicado: (2017)

Accumulation of CD103(+) CD8(+) T cells in a cutaneous melanoma micrometastasis
por: Hochheiser, Katharina, et al.
Publicado: (2019)

The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
por: Lim, Su Yin, et al.
Publicado: (2023)

Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors
por: Anaka, Matthew, et al.
Publicado: (2013)

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy
por: Prithviraj, Prashanth, et al.
Publicado: (2015)

Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma
por: Wong, Stephen Q., et al.
Publicado: (2014)

Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
por: Bowyer, Samantha, et al.
Publicado: (2017)

Identification of PDCD1 and PDCD1LG2 as Prognostic Biomarkers and Associated with Immune Infiltration in Hepatocellular Carcinoma
por: Li, Wang, et al.
Publicado: (2022)

Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients
por: Pirozyan, Mehdi R., et al.
Publicado: (2020)

Perspective: cancer vaccines in the era of immune checkpoint blockade
por: Cebon, Jonathan
Publicado: (2018)

Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
por: Nahar, Kazi J, et al.
Publicado: (2020)

A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC?
por: Eldafashi, Nardeen, et al.
Publicado: (2021)

VEGF Inhibitors Improve Survival Outcomes in Patients with Liver Metastases across Cancer Types—A Meta-Analysis
por: Conway, Jordan W., et al.
Publicado: (2023)

High response rate to PD-1 blockade in desmoplastic melanomas
por: Eroglu, Zeynep, et al.
Publicado: (2018)

Response to Letter to the Editor: “Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes”
por: Tsang, Venessa H M, et al.
Publicado: (2020)

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients
por: Gide, Tuba N., et al.
Publicado: (2019)

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
por: Lee, Erinna F., et al.
Publicado: (2019)

OTHR-08. PREDICTION OF RISK OF CENTRAL NERVOUS SYSTEM METASTASIS FOR AJCC 8(TH) EDITION STAGE III MELANOMA PATIENTS
por: Haydu, Lauren, et al.
Publicado: (2019)

Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities
por: Parakh, Sagun, et al.
Publicado: (2021)

Recombinant human PDCD5 (rhPDCD5) protein is protective in a mouse model of multiple sclerosis
por: Xiao, Juan, et al.
Publicado: (2015)

Association between PDCD1 gene polymorphisms and psoriasis susceptibility in the Chinese population
por: Hua, Shengyuan, et al.
Publicado: (2021)

Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report
por: Hultin, Sebastian, et al.
Publicado: (2020)

WWP2 ameliorates oxidative stress and inflammation in atherosclerotic mice through regulation of PDCD4/HO-1 pathway: WWP2 interacted with PDCD4 ameliorates AS
por: Wang, Xingye, et al.
Publicado: (2022)

Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538
por: Klein, Oliver, et al.
Publicado: (2021)

Phenotypic Differences in Thyroid Immune Related Adverse Events Following Treatment With Immune Checkpoint Inhibitors
por: Muir, Christopher Alan, et al.
Publicado: (2021)

Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
por: Diefenbach, Russell J., et al.
Publicado: (2022)

Translation, Pdcd4 and eIF4A
por: Biyanee, Abhiruchi, et al.
Publicado: (2015)

The multifaceted PDCD10/CCM3 gene
por: Valentino, Mariaelena, et al.
Publicado: (2020)

Dissecting the Roles of PDCD4 in Breast Cancer
por: Cai, Qian, et al.
Publicado: (2022)

Anti-Inflammatory Effects of Recombinant Human PDCD5 (rhPDCD5) in a Rat Collagen-Induced Model of Arthritis
por: Xiao, Juan, et al.
Publicado: (2014)

Molecular Characterisation and Functions of Fis1 and PDCD6 Genes from Echinococcus granulosus
por: Wang, Ning, et al.
Publicado: (2018)

Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population
por: Lee, Sang-Hoon, et al.
Publicado: (2006)

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
por: Deken, Marcel A., et al.
Publicado: (2016)

Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma
por: Cebon, Jonathan S, et al.
Publicado: (2020)

Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets
por: Gide, Tuba N., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ccbrjnt6cd06h3bv4nt32s38iq